Vilin Bio Med Past Earnings Performance
Past criteria checks 0/6
Vilin Bio Med has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 18.2% per year.
Key information
1.7%
Earnings growth rate
-2.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -18.2% |
| Return on equity | -2.1% |
| Net Margin | -3.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vilin Bio Med makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 131 | -5 | 6 | 0 |
| 30 Jun 24 | 146 | -2 | 7 | 0 |
| 31 Mar 24 | 161 | 2 | 8 | 0 |
| 31 Dec 23 | 152 | 4 | 7 | 0 |
| 30 Sep 23 | 160 | 15 | 8 | 0 |
| 30 Jun 23 | 142 | 14 | 8 | 0 |
| 31 Mar 23 | 123 | 12 | 8 | 0 |
| 31 Mar 22 | 112 | 0 | 9 | 0 |
| 31 Mar 21 | 117 | 1 | 11 | 0 |
| 31 Mar 20 | 168 | 2 | 14 | 0 |
Quality Earnings: VILINBIO is currently unprofitable.
Growing Profit Margin: VILINBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VILINBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare VILINBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VILINBIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: VILINBIO has a negative Return on Equity (-2.1%), as it is currently unprofitable.